Skip to main content
. 2020 May 11;4(9):2049–2057. doi: 10.1182/bloodadvances.2020001690

Figure 1.

Figure 1.

The anti-human C6 mAb 1C9 inhibits complement-mediated hemolysis in a dose-dependent manner. Different concentrations of 1C9 (0-30 nM) were assessed in a conventional complement-mediated hemolytic assay containing sensitized sheep RBCs and 1% normal human serum in GVB containing Ca++ and Mg++. Data represent mean ± standard deviation. Representative results from 3 independent experiments.